ArriVent BioPharma's Phase 3 trial for a lung cancer treatment failed to meet expectations due to unexpectedly strong results from chemotherapy patients. Analysts are now shifting attention to a late-stage test of the tyrosine kinase inhibitor in another lung cancer type and the company's antibody-drug conjugate pipeline.

ArriVent's stock plummeted over 50% following disappointing clinical trial results for its lung cancer treatment, significantly diminishing its market competitiveness against major players like Johnson & Johnson. The setback raises concerns about the company's future funding and strategic partnerships.

Merck and Daiichi Sankyo have halted plans to seek accelerated approval for their lung cancer antibody-drug conjugate, I-DXd, after the FDA indicated that current data is insufficient. This setback diminishes their competitive advantage in a rapidly evolving market.

Merck and Daiichi Sankyo have retracted their accelerated approval request for ifinatamab deruxtecan in lung cancer, a move seen as beneficial for competitors such as GSK and Roche. This decision reflects ongoing challenges in the ADC market.

New research highlights the role of low-density neutrophils as active drivers in breast and lung cancer, shifting their perception from passive bystanders. This discovery could inform future therapeutic strategies targeting these immune cells.